58 active not recruiting. 58 Phase 2, 22 Phase 1, 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 58 | Active not recruiting 58 |
| Phase 1 | 22 | Active not recruiting 22 |
| Phase 3 | 3 | Active not recruiting 3 |
Follow Lymphoma, Large B-Cell, Diffuse: new trials by email Literature Review of Lymphoma, Large B-Cell, Diffuse trials Research Report on Lymphoma, Large B-Cell, Diffuse
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety of Glofitamab Combined With GemOxin the Treatment of Refractory Diffuse Large B-Cell Lymphoma Glofitamab, Gemcitabin, Oxaliplatin - Refractory Diffuse Large B-Cell Lymphoma (DLBCL) | Phase 2 | Active not recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 40 | 2026-01-01 | 2026-03-18 |
| Efficacy and Safety of Sequential Autologous Hematopoietic Stem Cell Transplantation Combined With Tafasitamab, Lenalidomide, and Standard Immunochemotherapy for Relapsed/Refractory Diffuse Large B-cell Lymphoma Treatment with the Tafa+Len+ standard immunotherapy regimen (e.g., R-ICE, R-DHAP, R-GDP, etc.) - Relapsed/Refractory Diffuse Large B Cell Lymphoma | Phase 2 | Active not recruiting | The First Affiliated Hospital of Soochow University | 25 | 2026-01-01 | 2026-06-02 |
| Glofitamab in Relapsed or Refractory Diffuse Large B-cell Lymphoma After CD19 Chimeric Antigen Receptor T-cell Therapy Glofitamab - Diffuse Large B Cell Lymphoma | Phase 2 | Active not recruiting | Samsung Medical Center | 30 | 2024-11-26 | 2025-05-21 |
| Relmacabtagene Autoleucel As Second-Line Therapy in Adult Patients with Aggressive B-cell NHL Relmacabtagene Autoleucel, Fludarabine, Cyclophosphamide - Lymphoma, Large B-Cell, Diffuse, Follicular Lymphoma Grade 3B | Phase 2 | Active not recruiting | Shanghai Ming Ju Biotechnology Co., Ltd. | 46 | 2023-11-03 | 2025-02-11 |
| Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patients With Relapsed/ Refractory Large B-Cell Lymphoma Biopsy, Biospecimen Collection, Carboplatin - Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Phase 2 | Active not recruiting | David Bond, MD | 37 | 2023-06-29 | 2026-07-20 |
| TTI-622 in Combination With Pembrolizumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma Biospecimen Collection, Computed Tomography, Ontorpacept - Recurrent ALK Positive Large B-Cell Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma | Phase 2 | Active not recruiting | Mayo Clinic | 10 | 2023-04-19 | 2026-04-22 |
| Rituximab in Combination With Glofitamab and Polatuzumab Vedotin in Patients With Previously Untreated Aggressive B-cell Lymphoma Ineligible for R-CHOP Glofitamab, Rituximab, Obinutuzumab - Lymphoma, Large B-Cell, Diffuse | Phase 2 | Active not recruiting | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | 125 | 2023-03-20 | 2026-04-08 |
| Acalabrutinib + Liso-Cel In R/R Aggressive B-Cell Lymphomas ACALABRUTINIB, LISOCABTAGENE MARALEUCEL, Lymphodepleting chemotherapy - Refractory Aggressive B-cell Lymphomas, Refractory B-Cell Non-Hodgkin Lymphoma | Phase 2 | Active not recruiting | Patrick C. Johnson, MD | 28 | 2023-03-01 | 2026-01-29 |
| A Study of MT-2111 in Patients With Relapsed/Refractory DLBCL MT-2111 - Diffuse Large B-Cell Lymphoma | Phase 1 / Phase 2 | Active not recruiting | Tanabe Pharma Corporation | 46 | 2023-01-30 | 2026-06-09 |
| Tafasitamab, Retifanlimab, and Rituximab in Combination With Standard Therapy for the Treatment of Diffuse Large B-cell Lymphoma Bone Marrow Biopsy, Cyclophosphamide, Doxorubicin - Diffuse Large B-Cell Lymphoma, Grade 3b Follicular Lymphoma | Phase 1 / Phase 2 | Active not recruiting | University of Washington | 33 | 2023-01-26 | 2026-10-30 |
| Sepantronium Bromide for the Treatment of High-grade B-cell Lymphoma Sepantronium Bromide - High-grade B-cell Lymphoma, Burkitt Lymphoma | Phase 2 | Active not recruiting | Cothera Bioscience, Inc | 14 | 2022-12-09 | 2025-01-14 |
| Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas IMT-009, Fruquintinib - Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma | Phase 1 / Phase 2 | Active not recruiting | Immunitas Therapeutics | 67 | 2022-11-28 | 2025-10-16 |
| Study of Oral MRT-2359 in Selected Cancer Patients Oral MRT-2359 - NSCLC, SCLC | Phase 1 / Phase 2 | Active not recruiting | Monte Rosa Therapeutics, Inc | 174 | 2022-10-12 | 2026-03-03 |
| A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Classic Follicular Lymphoma Epcoritamab - Diffuse Large B-Cell Lymphoma, Classic Follicular Lymphoma | Phase 2 | Active not recruiting | Genmab | 184 | 2022-08-17 | 2026-09-11 |
| A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma JNJ-90014496 - Lymphoma, Non-Hodgkin, Lymphoma, B-Cell | Phase 1 / Phase 2 | Active not recruiting | Janssen Research & Development, LLC | 166 | 2022-08-12 | 2026-11-03 |
| A Study of GNC-038, a Tetra-specific Antibody, in Participants With R/R Diffuse Large B-cell Lymphoma (DLBCL) GNC-038 - Diffuse Large B-cell Lymphoma | Phase 1 / Phase 2 | Active not recruiting | Sichuan Baili Pharmaceutical Co., Ltd. | 12 | 2022-08-10 | 2025-09-26 |
| Safety and Pharmacokinetics Study of a Modified Tafasitamab IV Dosing Regimen Combined With Lenalidomide in R-R DLBCL Patients Tafasitamab, Lenalidomide - Diffuse Large B Cell Lymphoma | Phase 1 / Phase 2 | Active not recruiting | Incyte Corporation | 53 | 2022-07-19 | 2026-01-16 |
| Pembrolizumab in Combination With R-ICE Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma Pembrolizumab, Rituximab, Ifosfamide - Diffuse Large B Cell Lymphoma | Phase 2 | Active not recruiting | University of Southampton | 65 | 2022-06-27 | 2026-05-15 |
| A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma Epcoritamab, Lenalidomide, Ibrutinib - Non-Hodgkin Lymphoma | Phase 2 | Active not recruiting | Genmab | 264 | 2022-06-14 | 2026-07-07 |
| Phase 1/2 Study of CD19 Chimeric Antigen Receptor T-cell (CD19 CAR-T; PL001) for Relapsed or Refractory B-cell Lymphoma CD19-targeted chimeric antigen receptor T-cell - Diffuse Large B Cell Lymphoma, Primary Mediastinal Large B Cell Lymphoma | Phase 1 / Phase 2 | Active not recruiting | Pell Bio-Med Technology Co., Ltd. | 49 | 2022-05-31 | 2026-10-09 |
Showing 20 of 58. Sign in to see all of them.
Lymphoma, Non-Hodgkin (15) · Lymphoma, Follicular (13) · Lymphoma, B-Cell (12) · Lymphoma (8) · Lymphoma, B-Cell, Marginal Zone (8) · Lymphoma, Mantle-Cell (8) · Recurrence (7) · Leukemia, Lymphocytic, Chronic, B-Cell (6) · Burkitt Lymphoma (5) · Neoplasms (5) · Waldenstrom Macroglobulinemia (4) · Hodgkin Disease (3) · Neoplasms, Plasma Cell (3) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (3)
Hemic and Lymphatic Diseases (58) · Immune System Diseases (57) · Neoplasms by Histologic Type (57) · Immunoproliferative Disorders (56) · Lymphatic Diseases (56) · Lymphoproliferative Disorders (56) · Neoplasms (53) · Lymphoma (50) · Lymphoma, B-Cell (46) · Lymphoma, Non-Hodgkin (43) · Pathological Conditions, Signs and Symptoms (12) · Disease Attributes (11) · Pathologic Processes (11) · Hematologic Diseases (9) · Leukemia (8)
Rituximab (21) · Cyclophosphamide (20) · Doxorubicin (15) · Prednisone (13) · Lenalidomide (11) · Vincristine (11) · Etoposide (9) · CT-P10 (7) · acalabrutinib (6) · polatuzumab vedotin (6) · Magnetic Resonance Spectroscopy (5) · R-CHOP protocol (5) · deltacortene (5) · glofitamab (5) · tafasitamab (5)
Genmab (4) · National Cancer Institute (NCI) (3) · University of Washington (3) · Barbara Ann Karmanos Cancer Institute (2) · City of Hope Medical Center (2) · David Bond, MD (2) · Karyopharm Therapeutics Inc (2) · M.D. Anderson Cancer Center (2) · AIDS Malignancy Consortium (1) · ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) (1) · Bambino Gesù Hospital and Research Institute (1) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1) · Cellectar Biosciences, Inc. (1) · Cothera Bioscience, Inc (1) · Dana-Farber Cancer Institute (1)
United States (38) · China (9) · Spain (9) · France (8) · Italy (8) · United Kingdom (8) · South Korea (7) · Australia (6) · Japan (6) · Germany (5) · Israel (5) · Austria (4) · Czechia (4) · Netherlands (4) · Poland (4)
David A Bond, MD (2) · Dipenkumar Modi, M.D. (2) · Ajay Gopal (1) · Alex F Herrera (1) · Anastasios Stathis, Prof (1) · Andrew Davies (1) · Auayporn P. Nademanee, MD (1) · Cao Xinxin (1) · Chen-Lung Lin, MD (1) · Christopher Fletcher, MD (1) · Connor Johnson, MD (1) · Depei Wu, PhD (1) · Elizabeth A Brem (1)
PMID 39319495, PMID 32589977, PMID 33206936, PMID 33528286, PMID 33785483, PMID 34271963, PMID 34398557, PMID 34515338, PMID 34634256, PMID 34686472, PMID 35015819, PMID 35078739, PMID 35952327, PMID 36521030, PMID 37930156, PMID 39300447, PMID 39792928, PMID 40097657, PMID 40472301, PMID 40632620, PMID 40802906, PMID 40829156, PMID 40902079, PMID 40920572, PMID 41563911, PMID 41766170, PMID 41784015, PMID 41845899, PMID 42411504, PMID 42541678, PMID 42622258, PMID 42660129, PMID 42660130, PMID 42784255
2023 (4), P30CA022453 (2), P30CA033572 (2), 2014 (1), 2017 (1), 2019 (1), P30CA060553 (1), U01CA121947 (1), U10CA180821 (1), U10CA180888 (1), UL1TR002240 (1), UM1CA186686 (1), UM1CA186709 (1)